• Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48
• Four presentations build on the previously reported Phase 3 RINGSIDE results

Immunome, Inc. (NASDAQ:IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the presentation of additional clinical data for varegacestat, its investigational, oral, once-daily gamma secretase inhibitor, at the 2026 European Society for Medical Oncology (ESMO) Congress. The data were featured in four presentations, including a rapid oral presentation on patient-reported outcomes from the Phase 3 RINGSIDE trial in patients with progressing desmoid tumors and three posters providing further analyses of varegacestat’s clinical profile.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.